Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naive chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1991 and is headquartered in Wilmington, Delaware. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Pasquale Maria E | EVP & General Counsel | Jan 11 | Option Exercise | 65.36 | 127 | 8,301 | 30,073 | Jan 13 04:15 PM | Pasquale Maria E | EVP & General Counsel | Dec 11 | Option Exercise | 65.36 | 128 | 8,366 | 29,946 | Dec 15 04:51 PM | Pasquale Maria E | EVP & General Counsel | Nov 12 | Option Exercise | 65.36 | 127 | 8,301 | 28,586 | Nov 16 04:56 PM | BIENAIME JEAN JACQUES | Director | Nov 10 | Sale | 83.00 | 798 | 66,234 | 8,646 | Nov 12 04:41 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Nov 06 | Option Exercise | 65.42 | 961 | 62,869 | 28,971 | Nov 10 04:26 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Nov 06 | Sale | 85.17 | 961 | 81,848 | 28,010 | Nov 10 04:26 PM | Flannelly Barry P | EVP & General Manager US | Nov 02 | Option Exercise | 48.44 | 20,000 | 968,800 | 59,984 | Nov 04 04:15 PM | Flannelly Barry P | EVP & General Manager US | Nov 02 | Sale | 86.60 | 20,000 | 1,732,000 | 39,984 | Nov 04 04:15 PM | Pasquale Maria E | EVP & General Counsel | Oct 12 | Option Exercise | 65.36 | 128 | 8,366 | 28,459 | Oct 13 05:10 PM | Pasquale Maria E | EVP & General Counsel | Oct 09 | Option Exercise | 68.62 | 1,423 | 97,646 | 29,754 | Oct 13 05:10 PM | Pasquale Maria E | EVP & General Counsel | Oct 09 | Sale | 95.00 | 1,423 | 135,185 | 28,331 | Oct 13 05:10 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Oct 06 | Option Exercise | 65.42 | 961 | 62,869 | 28,971 | Oct 08 04:21 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Oct 06 | Sale | 91.97 | 961 | 88,383 | 28,010 | Oct 08 04:21 PM | Pasquale Maria E | EVP & General Counsel | Sep 11 | Option Exercise | 65.36 | 127 | 8,301 | 28,331 | Sep 14 04:19 PM | Pasquale Maria E | EVP & General Counsel | Sep 10 | Option Exercise | 65.36 | 2,193 | 143,334 | 30,397 | Sep 14 04:19 PM | Pasquale Maria E | EVP & General Counsel | Sep 10 | Sale | 90.83 | 2,193 | 199,190 | 28,204 | Sep 14 04:19 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Sep 08 | Option Exercise | 65.42 | 961 | 62,869 | 28,971 | Sep 10 04:21 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Sep 08 | Sale | 88.94 | 961 | 85,471 | 28,010 | Sep 10 04:21 PM | DIXON WENDY L | Director | Aug 27 | Option Exercise | 18.97 | 20,000 | 379,400 | 34,243 | Aug 31 04:26 PM | DIXON WENDY L | Director | Aug 27 | Sale | 94.51 | 20,000 | 1,890,200 | 14,243 | Aug 31 04:26 PM | Pasquale Maria E | EVP & General Counsel | Aug 10 | Option Exercise | 65.36 | 128 | 8,366 | 28,204 | Aug 12 04:08 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Aug 06 | Option Exercise | 65.42 | 961 | 62,869 | 28,971 | Aug 10 04:20 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Aug 06 | Sale | 97.80 | 961 | 93,986 | 28,010 | Aug 10 04:20 PM | Stein Steven H | EVP & Chief Medical Officer | Jul 16 | Sale | 103.83 | 766 | 79,534 | 95,468 | Jul 17 04:20 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Jul 13 | Option Exercise | 65.42 | 2,419 | 158,251 | 28,010 | Jul 14 04:31 PM | Pasquale Maria E | EVP & General Counsel | Jul 10 | Option Exercise | 65.36 | 127 | 8,301 | 28,076 | Jul 14 04:39 PM | Stein Steven H | EVP & Chief Medical Officer | Jul 08 | Sale | 108.56 | 610 | 66,222 | 96,857 | Jul 08 05:27 PM | Iyengar Vijay K | EVP GPS, BD, & Licensing | Jul 08 | Sale | 108.56 | 475 | 51,566 | 25,926 | Jul 08 05:31 PM | Hoppenot Herve | Chairman / CEO | Jul 07 | Option Exercise | 73.21 | 89,771 | 6,572,135 | 354,907 | Jul 07 07:18 PM | Stein Steven H | EVP & Chief Medical Officer | Jul 07 | Option Exercise | 88.68 | 10,876 | 964,484 | 108,245 | Jul 08 05:27 PM | Iyengar Vijay K | EVP GPS, BD, & Licensing | Jul 07 | Sale | 107.98 | 3,120 | 336,898 | 26,401 | Jul 08 05:31 PM | Stein Steven H | EVP & Chief Medical Officer | Jul 07 | Sale | 109.56 | 14,159 | 1,551,326 | 97,467 | Jul 08 05:27 PM | Hoppenot Herve | Chairman / CEO | Jul 07 | Sale | 110.00 | 89,771 | 9,874,810 | 266,501 | Jul 07 07:18 PM | Wenqing Yao | EVP, Head of Discovery Chem | Jul 06 | Option Exercise | 64.55 | 16,553 | 1,068,496 | 171,906 | Jul 07 07:30 PM | Stein Steven H | EVP & Chief Medical Officer | Jul 06 | Option Exercise | 75.52 | 33,602 | 2,537,457 | 112,882 | Jul 07 07:25 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Jul 06 | Option Exercise | 65.42 | 961 | 62,869 | 26,552 | Jul 07 07:13 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Jul 06 | Sale | 106.58 | 961 | 102,423 | 25,591 | Jul 07 07:13 PM | Stein Steven H | EVP & Chief Medical Officer | Jul 06 | Sale | 107.25 | 36,124 | 3,874,171 | 100,750 | Jul 07 07:25 PM | Wenqing Yao | EVP, Head of Discovery Chem | Jul 06 | Sale | 107.32 | 16,553 | 1,776,468 | 156,258 | Jul 07 07:30 PM | Hoppenot Herve | Chairman / CEO | Jun 26 | Option Exercise | 64.55 | 124,148 | 8,013,753 | 360,104 | Jun 30 04:06 PM | Hoppenot Herve | Chairman / CEO | Jun 26 | Sale | 102.91 | 124,148 | 12,776,071 | 240,603 | Jun 30 04:06 PM | Flannelly Barry P | EVP & General Manager US | Jun 23 | Option Exercise | 73.21 | 599 | 43,853 | 36,461 | Jun 25 05:09 PM | Trower Paul | Principal Accounting Officer | Jun 23 | Option Exercise | 64.55 | 6,943 | 448,171 | 28,677 | Jun 25 05:15 PM | Trower Paul | Principal Accounting Officer | Jun 23 | Sale | 110.00 | 6,943 | 763,730 | 21,734 | Jun 25 05:15 PM | Flannelly Barry P | EVP & General Manager US | Jun 23 | Sale | 110.00 | 400 | 44,000 | 36,061 | Jun 25 05:09 PM | Dickinson Jonathan Elliott | EVP, General Manager, Europe | Jun 22 | Sale | 105.31 | 9,000 | 947,790 | 21,762 | Jun 23 04:17 PM | Iyengar Vijay K | EVP GPS, BD, & Licensing | Jun 19 | Option Exercise | 72.86 | 7,866 | 573,117 | 32,767 | Jun 23 04:33 PM | Pasquale Maria E | EVP & General Counsel | Jun 19 | Option Exercise | 72.27 | 1,423 | 102,840 | 25,084 | Jun 23 04:42 PM | Flannelly Barry P | EVP & General Manager US | Jun 19 | Option Exercise | 73.21 | 7,181 | 525,721 | 43,043 | Jun 23 04:23 PM | Pasquale Maria E | EVP & General Counsel | Jun 19 | Sale | 100.00 | 1,423 | 142,300 | 23,661 | Jun 23 04:42 PM | Iyengar Vijay K | EVP GPS, BD, & Licensing | Jun 19 | Sale | 105.00 | 7,866 | 825,930 | 24,901 | Jun 23 04:33 PM | Flannelly Barry P | EVP & General Manager US | Jun 19 | Sale | 105.00 | 7,181 | 754,005 | 35,862 | Jun 23 04:23 PM | Pasquale Maria E | EVP & General Counsel | Jun 12 | Option Exercise | 65.36 | 127 | 8,301 | 23,661 | Jun 16 04:24 PM | Pasquale Maria E | EVP & General Counsel | Jun 10 | Option Exercise | 66.64 | 3,615 | 240,915 | 25,726 | Jun 12 04:11 PM | Pasquale Maria E | EVP & General Counsel | Jun 10 | Sale | 94.51 | 3,615 | 341,649 | 23,534 | Jun 12 04:11 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Jun 08 | Option Exercise | 65.42 | 961 | 62,869 | 20,948 | Jun 10 04:34 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Jun 08 | Sale | 91.87 | 961 | 88,287 | 19,987 | Jun 10 04:34 PM | BAKER BROS. ADVISORS LP | Director | May 28 | Buy | 102.55 | 2 | 205 | 29,313,198 | May 28 08:07 PM | Pasquale Maria E | EVP & General Counsel | May 11 | Option Exercise | 65.36 | 128 | 8,366 | 23,534 | May 13 04:38 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | May 06 | Option Exercise | 65.42 | 961 | 62,869 | 20,948 | May 08 04:53 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | May 06 | Sale | 96.84 | 961 | 93,063 | 19,987 | May 08 04:53 PM | BAKER BROS. ADVISORS LP | Director | Apr 28 | Option Exercise | 13.34 | 40,000 | 533,600 | 29,311,915 | Apr 29 04:45 PM | Pasquale Maria E | EVP & General Counsel | Apr 17 | Option Exercise | 72.27 | 9,488 | 685,698 | 32,837 | Apr 20 05:08 PM | Flannelly Barry P | EVP & General Manager US | Apr 17 | Option Exercise | 73.21 | 6,583 | 481,941 | 41,925 | Apr 21 04:28 PM | Trower Paul | Principal Accounting Officer | Apr 17 | Option Exercise | 64.55 | 1,143 | 73,781 | 22,467 | Apr 21 04:35 PM | Trower Paul | Principal Accounting Officer | Apr 17 | Sale | 100.00 | 1,143 | 114,300 | 21,324 | Apr 21 04:35 PM | Flannelly Barry P | EVP & General Manager US | Apr 17 | Sale | 100.00 | 6,583 | 658,300 | 35,342 | Apr 21 04:28 PM | Pasquale Maria E | EVP & General Counsel | Apr 17 | Sale | 100.00 | 9,488 | 948,800 | 22,899 | Apr 20 05:08 PM | Pasquale Maria E | EVP & General Counsel | Apr 16 | Option Exercise | 68.62 | 9,488 | 651,067 | 32,837 | Apr 20 05:08 PM | Pasquale Maria E | EVP & General Counsel | Apr 16 | Sale | 95.00 | 9,488 | 901,360 | 22,899 | Apr 20 05:08 PM | Pasquale Maria E | EVP & General Counsel | Apr 14 | Option Exercise | 65.36 | 17,827 | 1,165,173 | 40,726 | Apr 15 04:57 PM | Pasquale Maria E | EVP & General Counsel | Apr 14 | Sale | 90.00 | 17,827 | 1,604,430 | 22,899 | Apr 15 04:57 PM | Pasquale Maria E | EVP & General Counsel | Apr 13 | Option Exercise | 65.36 | 127 | 8,301 | 23,864 | Apr 15 04:57 PM | Pasquale Maria E | EVP & General Counsel | Apr 13 | Sale | 85.68 | 965 | 82,681 | 22,899 | Apr 15 04:57 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Apr 06 | Option Exercise | 65.42 | 3,844 | 251,474 | 23,831 | Apr 08 04:35 PM | Pasquale Maria E | EVP & General Counsel | Apr 06 | Sale | 85.00 | 1,842 | 156,570 | 24,254 | Apr 08 04:39 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Apr 06 | Sale | 85.00 | 3,844 | 326,740 | 19,987 | Apr 08 04:35 PM | SWAIN PAULA J | EVP, Human Resources | Mar 31 | Option Exercise | 64.55 | 2,329 | 150,337 | 50,132 | Apr 02 05:32 PM | SWAIN PAULA J | EVP, Human Resources | Mar 31 | Sale | 71.44 | 2,329 | 166,384 | 48,493 | Apr 02 05:32 PM | Pasquale Maria E | EVP & General Counsel | Mar 11 | Option Exercise | 65.36 | 128 | 8,366 | 26,096 | Mar 13 04:18 PM | BROOKE PAUL A | Director | Feb 21 | Option Exercise | 13.34 | 20,000 | 266,800 | 221,584 | Feb 25 04:39 PM | SWAIN PAULA J | EVP, Human Resources | Feb 19 | Option Exercise | 64.55 | 2,500 | 161,375 | 50,993 | Feb 21 04:11 PM | SWAIN PAULA J | EVP, Human Resources | Feb 19 | Sale | 80.00 | 2,500 | 200,000 | 48,493 | Feb 21 04:11 PM | Pasquale Maria E | EVP & General Counsel | Feb 10 | Option Exercise | 65.36 | 127 | 8,301 | 19,087 | Feb 12 05:00 PM | Wenqing Yao | EVP, Head of Discovery Chem | Feb 05 | Option Exercise | 18.32 | 17,542 | 321,369 | 112,850 | Feb 07 04:48 PM | Wenqing Yao | EVP, Head of Discovery Chem | Feb 05 | Sale | 75.97 | 17,542 | 1,332,666 | 95,308 | Feb 07 04:48 PM |
|